Cepheid gets FDA clearance for blood clot test
Cepheid receives FDA clearance for test aimed at determining genetic risks for blood clots
- On 5:51 pm EDT, Thursday September 24, 2009
NEW YORK (AP) -- Cepheid said Thursday it received Food and Drug Administration clearance for its Xpert test aimed at determining a person's genetic risk of developing blood clots.
The Xpert HemosIL FII & FV test is a 30-minute genetic test that analyzes genetic factors associated with thrombosis, or blood clots.
Shares of Cepheid rose 68 cents, or 5.1 percent, to $14.12 in after-hours trading, after falling 80 cents, or 5.6 percent, to close at $13.44 during the regular trading session.
Related Headlines
- CEPHEID Financials - EDGAR Online Financials
- Cepheid to Webcast Upcoming Financial Presentations - PR Newswire
- CEPHEID Files SEC form 10-Q, Quarterly Report - EDGAR Online
- Cepheid Earnings Call scheduled for 5:00 pm ET today - CCBN
- CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - EDGAR Online
Related Blog Headlines
- Cepheid Narrows Loss - Zacks.com
- Celera Posts Break-Even Earnings - Zacks.com
Sponsored Links
-
Live Forex Practice Account
Practice Forex Trading in Real Market Conditions with a Free Trial. -
2.00-2.30% Apply Online
From AA+ Rated GE Capital Corp. Not An Offer Of Securities For Sale.
-
Super Cheap Car Insurance
Get Discount Car Insurance Quotes Online – Rates from $15 / Month. -
Buy Stocks for $4
No account or investment minimums. No inactivity fees. Start Today.
Tech Ticker Recent Posts
Add Alert Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.